Sarilumab scores over adalimumab in improving physical function in RA: Study
The study is published in the Journal of Arthritis and Research Therapy.
Increased levels of cytokines, including interleukin-6 (IL-6), reflect inflammation and have been shown to be predictive of therapeutic responses, fatigue, pain, and depression in patients with rheumatoid arthritis (RA), but limited data exist on associations between IL-6 levels and health-related quality of life (HRQoL).
Therefore, Vibeke Strand and colleagues from the Stanford University, Palo Alto, CA, US conducted the MONARCH phase III randomized controlled trial to evaluate the potential of baseline IL-6 levels to differentially predict HRQoL improvements with sarilumab.
Sarilumab is a fully human monoclonal antibody directed against both soluble and membrane-bound IL-6 receptor α (anti-IL-6Rα) whereas adalimumab is a tumor necrosis factor α inhibitor, both of which are approved for treatment of active Rheumatoid Arthritis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.